华润双鹤：控股子公司浙江新赛科药业有限公司通过GMP符合性检查

Core Viewpoint - China Resources Double Crane (华润双鹤) announced that its subsidiary, Zhejiang Xinsai Ke, received a GMP compliance inspection notice from the Zhejiang Provincial Drug Administration for the active pharmaceutical ingredients (APIs) of Fenofibrate and Azilsartan. This marks the first inspection before the market launch of these APIs, and no additional funding was required for this process [1]. Summary by Category - Company Announcement - China Resources Double Crane's subsidiary, Zhejiang Xinsai Ke, has received a GMP compliance inspection notice for Fenofibrate and Azilsartan APIs [1]. - This inspection is the first before the market launch of these products [1]. - The company did not incur any additional costs for this inspection [1].